CD30-Positive Extracellular Vesicles Enable the Targeting of CD30-Negative DLBCL Cells by the CD30 Antibody-Drug Conjugate Brentuximab Vedotin

CD30-Positive Extracellular Vesicles Enable the Targeting of CD30-Negative DLBCL Cells by the CD30 Antibody-Drug Conjugate Brentuximab Vedotin

CD30, a member of the TNF receptor superfamily, is selectively expressed on a subset of activated lymphocytes and on malignant cells of certain lymphomas, such as classical Hodgkin Lymphoma (cHL), where it activates critical bystander cells in the tumor microenvironment. Therefore, it is not surpris...

Full description

Bibliographic Details
Main Authors: Liudmila Lobastova, Marcus Lettau, Felix Babatz, Thais Dolzany de Oliveira, Phuong-Hien Nguyen, Bianca Alves Pauletti, Astrid C. Schauss, Horst Dürkop, Ottmar Janssen, Adriana F. Paes Leme, Michael Hallek, Hinrich P. Hansen
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-07-01
Series:Frontiers in Cell and Developmental Biology
Subjects:
tumor microenvironment
cellular crosstalk
immune therapy
antibody-drug conjugate
extracellular vesicle
Online Access:https://www.frontiersin.org/articles/10.3389/fcell.2021.698503/full

Internet

https://www.frontiersin.org/articles/10.3389/fcell.2021.698503/full

Similar Items